Obinutuzumab
Information
- Drug Name
- Obinutuzumab
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02867384 | Active, not recruiting | Phase 2 | Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation | November 29, 2016 | October 31, 2024 |
| NCT02871219 | Active, not recruiting | Phase 2 | Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma | December 6, 2016 | July 23, 2024 |
| NCT02537613 | Active, not recruiting | Phase 1 | A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | December 2015 | January 2029 |
| NCT02896582 | Active, not recruiting | Phase 2 | Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance | October 2016 | March 2025 |
| NCT05105841 | Active, not recruiting | Phase 2 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | November 8, 2021 | October 26, 2025 |
| NCT05057494 | Active, not recruiting | Phase 3 | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | September 12, 2022 | April 10, 2029 |
| NCT05050214 | Active, not recruiting | Phase 2 | Obinutuzumab in Primary MN | February 18, 2022 | April 2025 |
| NCT04983888 | Active, not recruiting | Phase 2 | Obinutuzumab in Primary FSGS | November 17, 2021 | September 2025 |
| NCT05387616 | Active, not recruiting | Phase 2 | A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden | October 19, 2020 | May 19, 2026 |
| NCT05211336 | Active, not recruiting | Phase 1 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | April 19, 2022 | June 1, 2029 |
| NCT02992522 | Active, not recruiting | Phase 1 | Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | February 21, 2017 | December 31, 2024 |
| NCT04826003 | Active, not recruiting | Phase 1/Phase 2 | Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment | July 14, 2021 | December 27, 2024 |
| NCT04722172 | Active, not recruiting | Phase 2 | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | May 21, 2021 | February 2025 |
| NCT04608318 | Active, not recruiting | Phase 3 | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | March 1, 2021 | March 2027 |
| NCT04599634 | Active, not recruiting | Phase 1 | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | December 16, 2021 | February 8, 2027 |
| NCT04703686 | Active, not recruiting | Phase 2 | Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | March 30, 2021 | March 1, 2026 |
| NCT04578600 | Active, not recruiting | Phase 1 | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | October 23, 2020 | December 2024 |
| NCT02629809 | Active, not recruiting | Phase 2 | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | March 18, 2016 | March 31, 2025 |
| NCT04515238 | Active, not recruiting | Phase 2 | Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL | October 1, 2020 | March 2027 |
| NCT04464798 | Active, not recruiting | Phase 1 | A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas | November 11, 2020 | January 2, 2025 |
| NCT03198650 | Active, not recruiting | Phase 1 | A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies | June 27, 2017 | December 13, 2024 |
| NCT04447768 | Active, not recruiting | Phase 2 | The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) | December 3, 2020 | July 2026 |
| NCT04434196 | Active, not recruiting | Phase 1 | A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | December 21, 2020 | May 13, 2025 |
| NCT02296918 | Active, not recruiting | Phase 1 | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | December 22, 2014 | September 6, 2027 |
| NCT02427451 | Active, not recruiting | Phase 1/Phase 2 | Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia | August 3, 2015 | December 31, 2024 |
| NCT04285567 | Active, not recruiting | Phase 3 | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation | May 28, 2020 | July 31, 2026 |
| NCT03322865 | Active, not recruiting | Phase 2 | Obinutuzumab in Marginal Zone Lymphoma | November 23, 2018 | November 30, 2028 |
| NCT03332017 | Active, not recruiting | Phase 2 | A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma | November 14, 2017 | October 31, 2024 |
| NCT04221477 | Active, not recruiting | Phase 3 | A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis | August 10, 2020 | February 28, 2029 |
| NCT02242942 | Active, not recruiting | Phase 3 | Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | December 31, 2014 | August 31, 2025 |
| NCT03401853 | Active, not recruiting | Phase 2 | Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma | March 23, 2018 | December 19, 2025 |
| NCT02457598 | Active, not recruiting | Phase 1 | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | June 16, 2015 | December 2025 |
| NCT03410875 | Active, not recruiting | Phase 2 | A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | February 9, 2018 | January 2025 |
| NCT02475681 | Active, not recruiting | Phase 3 | Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL | June 26, 2015 | September 30, 2025 |
| NCT03462719 | Active, not recruiting | Phase 3 | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | April 17, 2018 | April 5, 2027 |
| NCT03872180 | Active, not recruiting | Phase 2 | Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | April 11, 2019 | April 30, 2026 |
| NCT03737981 | Active, not recruiting | Phase 3 | Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | January 31, 2019 | June 1, 2027 |
| NCT04629248 | Active, not recruiting | Phase 3 | A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy | June 25, 2021 | December 29, 2027 |
| NCT03533283 | Active, not recruiting | Phase 1/Phase 2 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | May 8, 2018 | September 30, 2026 |
| NCT03836261 | Active, not recruiting | Phase 3 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | February 25, 2019 | January 6, 2027 |
| NCT03580928 | Active, not recruiting | Phase 2 | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL | August 7, 2018 | December 31, 2027 |
| NCT03701282 | Active, not recruiting | Phase 3 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | February 12, 2019 | May 7, 2028 |
| NCT02750670 | Completed | Phase 2 | Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | March 15, 2017 | February 9, 2021 |
| NCT02758665 | Completed | Phase 2 | Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL | September 2016 | March 2022 |
| NCT02877550 | Completed | Phase 1 | Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients | February 15, 2017 | May 4, 2022 |
| NCT02915224 | Completed | A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities | November 23, 2016 | June 8, 2021 | |
| NCT02950051 | Completed | Phase 3 | Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation | December 13, 2016 | February 29, 2024 |
| NCT02962401 | Completed | Phase 2 | Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia | March 7, 2017 | April 13, 2023 |
| NCT02968563 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | December 13, 2016 | January 14, 2021 |
| NCT02983617 | Completed | Phase 2 | Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL) | April 6, 2017 | October 1, 2020 |
| NCT02987400 | Completed | Phase 2 | Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL | January 4, 2017 | October 19, 2021 |
| NCT03010358 | Completed | Phase 1/Phase 2 | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | July 17, 2017 | April 29, 2021 |
| NCT03059251 | Completed | Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina | August 31, 2017 | March 30, 2019 | |
| NCT03113695 | Completed | Phase 1 | Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome | December 20, 2017 | May 2, 2022 |
| NCT04551352 | Completed | Phase 1 | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | October 28, 2020 | July 28, 2022 |
| NCT04313608 | Completed | Phase 1 | A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma | June 4, 2020 | October 26, 2021 |
| NCT03276468 | Completed | Phase 2 | Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas | February 12, 2018 | August 24, 2022 |
| NCT03374137 | Completed | Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia | March 9, 2018 | November 10, 2022 | |
| NCT03406156 | Completed | Phase 3 | A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | August 10, 2018 | July 10, 2023 |
| NCT04034056 | Completed | Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) | September 2, 2019 | April 22, 2024 | |
| NCT03492775 | Completed | Phase 2 | First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years | December 12, 2017 | December 31, 2022 |
| NCT03866239 | Completed | Phase 1 | A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma | May 7, 2019 | March 13, 2024 |
| NCT03817853 | Completed | Phase 4 | An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma | February 26, 2019 | January 25, 2023 |
| NCT00825149 | Completed | Phase 1 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma | February 2009 | November 2015 |
| NCT01010061 | Completed | Phase 3 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | December 21, 2009 | August 23, 2017 |
| NCT01059630 | Completed | Phase 3 | A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) | April 30, 2010 | November 30, 2018 |
| NCT00517530 | Completed | Phase 1/Phase 2 | A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN) | September 2007 | November 2013 |
| NCT01300247 | Completed | Phase 1 | A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON) | May 2011 | December 2015 |
| NCT01332968 | Completed | Phase 3 | A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) | July 6, 2011 | July 30, 2021 |
| NCT01414205 | Completed | Phase 2 | A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) | October 31, 2011 | March 31, 2016 |
| NCT01414855 | Completed | Phase 2 | A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) | August 31, 2011 | December 23, 2016 |
| NCT01671904 | Completed | Phase 1 | A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) | January 13, 2014 | August 11, 2020 |
| NCT01680991 | Completed | Phase 1 | A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease | September 2012 | December 2014 |
| NCT01685892 | Completed | Phase 1 | A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia | November 29, 2012 | August 23, 2019 |
| NCT01691898 | Completed | Phase 1/Phase 2 | A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | September 27, 2012 | February 7, 2019 |
| NCT01868893 | Completed | Phase 2 | An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia | August 2013 | January 2014 |
| NCT01905943 | Completed | Phase 3 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | November 4, 2013 | October 8, 2018 |
| NCT01992653 | Completed | Phase 1/Phase 2 | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | November 29, 2013 | December 19, 2018 |
| NCT01995669 | Completed | Phase 1/Phase 2 | Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma | May 21, 2014 | January 23, 2023 |
| NCT01998880 | Completed | Phase 3 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | December 22, 2009 | August 23, 2017 |
| NCT02053610 | Completed | Phase 3 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | December 31, 2009 | August 23, 2017 |
| NCT02055820 | Completed | Phase 1/Phase 2 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | November 17, 2013 | June 28, 2019 |
| NCT02071225 | Completed | Phase 2 | A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia | April 9, 2014 | November 19, 2018 |
| NCT02174172 | Completed | Phase 1 | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors | August 18, 2014 | November 25, 2019 |
| NCT02220842 | Completed | Phase 1 | A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | December 18, 2014 | January 21, 2020 |
| NCT02257567 | Completed | Phase 1/Phase 2 | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma | October 15, 2014 | October 21, 2021 |
| NCT02264574 | Completed | Phase 3 | A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | October 6, 2014 | September 3, 2019 |
| NCT02320487 | Completed | Phase 2 | A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | March 31, 2015 | February 6, 2019 |
| NCT02324257 | Completed | Phase 1 | A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors | December 30, 2014 | September 3, 2019 |
| NCT02406742 | Completed | Phase 1/Phase 2 | A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | July 27, 2015 | July 7, 2020 |
| NCT02417285 | Completed | Phase 1 | A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. | May 22, 2015 | September 28, 2023 |
| NCT04880863 | Completed | Phase 2 | Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC | October 26, 2021 | January 30, 2024 |
| NCT02453087 | Completed | Phase 1 | A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | August 4, 2015 | July 12, 2019 |
| NCT02529852 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma | November 4, 2015 | October 31, 2022 |
| NCT02550652 | Completed | Phase 2 | A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN) | November 13, 2015 | August 2, 2023 |
| NCT02569476 | Completed | Phase 1 | BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies | January 13, 2016 | September 2, 2020 |
| NCT02586051 | Completed | Phase 1 | A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation | November 19, 2015 | November 26, 2018 |
| NCT02596971 | Completed | Phase 1/Phase 2 | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) | December 22, 2015 | May 8, 2020 |
| NCT02600897 | Completed | Phase 1/Phase 2 | A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | March 24, 2016 | December 15, 2021 |
| NCT02611323 | Completed | Phase 1/Phase 2 | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | March 9, 2016 | August 4, 2022 |
| NCT02631577 | Completed | Phase 1/Phase 2 | A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | December 31, 2015 | October 7, 2020 |
| NCT04657302 | Completed | Phase 1 | A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | January 8, 2021 | January 12, 2024 |
| NCT02729896 | Completed | Phase 1/Phase 2 | A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | November 9, 2016 | October 7, 2019 |
| NCT02736617 | Completed | Phase 2 | Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma | July 5, 2016 | June 2, 2021 |
| NCT03787264 | Completed | Phase 2 | Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL | January 14, 2019 | September 26, 2023 |
| NCT03755947 | Completed | Phase 2 | Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia | December 1, 2018 | February 1, 2021 |
| NCT05797948 | Enrolling by invitation | N/A | GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | July 1, 2022 | June 30, 2024 |
| NCT06428019 | Not yet recruiting | Phase 3 | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | June 6, 2024 | October 21, 2026 |
| NCT04920968 | Not yet recruiting | Phase 2 | Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 OVERALL | June 30, 2021 | December 31, 2024 |
| NCT05968001 | Not yet recruiting | Obinutuzumab in Chinese Real-world Patients With iNHL | July 20, 2023 | July 20, 2026 | |
| NCT06071871 | Not yet recruiting | Phase 2 | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma | April 30, 2024 | July 31, 2028 |
| NCT06120673 | Not yet recruiting | Phase 3 | REmission in Membranous Nephropathy International Trial (REMIT) | July 31, 2024 | January 31, 2028 |
| NCT06252675 | Not yet recruiting | Phase 2 | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | May 1, 2024 | March 31, 2028 |
| NCT06291220 | Not yet recruiting | Phase 1 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | June 2, 2024 | July 21, 2029 |
| NCT06357676 | Not yet recruiting | Phase 1/Phase 2 | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma | May 1, 2024 | May 1, 2029 |
| NCT03930953 | Recruiting | Phase 1/Phase 2 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) | May 20, 2019 | April 18, 2027 |
| NCT05364424 | Recruiting | Phase 1 | A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma | November 4, 2022 | December 31, 2024 |
| NCT05533775 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | November 16, 2022 | October 15, 2027 |
| NCT05536349 | Recruiting | Phase 2 | Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | December 20, 2022 | April 25, 2025 |
| NCT05627557 | Recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome | March 29, 2023 | August 15, 2026 |
| NCT05653271 | Recruiting | Phase 1 | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | January 21, 2023 | September 2027 |
| NCT05783596 | Recruiting | Phase 2 | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | July 18, 2023 | January 8, 2029 |
| NCT05798156 | Recruiting | Phase 2 | Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP | March 20, 2023 | September 30, 2028 |
| NCT05823701 | Recruiting | Phase 2 | Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | September 30, 2022 | December 31, 2025 |
| NCT05833763 | Recruiting | Phase 2 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. | October 12, 2023 | April 2037 |
| NCT05846750 | Recruiting | Phase 2 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma | November 1, 2022 | May 31, 2028 |
| NCT05848765 | Recruiting | Phase 2 | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | September 4, 2023 | November 30, 2031 |
| NCT05861050 | Recruiting | Phase 1/Phase 2 | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | August 10, 2023 | February 1, 2026 |
| NCT05896163 | Recruiting | Phase 1/Phase 2 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. | August 30, 2023 | June 19, 2028 |
| NCT05899621 | Recruiting | A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL | June 1, 2023 | June 30, 2027 | |
| NCT05943496 | Recruiting | Phase 1 | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia | October 2, 2023 | January 1, 2027 |
| NCT05950997 | Recruiting | N/A | A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL | April 16, 2024 | September 30, 2026 |
| NCT06284122 | Recruiting | Phase 3 | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 | May 2024 | April 2034 |
| NCT06043674 | Recruiting | Phase 2 | A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation | January 22, 2024 | January 15, 2033 |
| NCT06054776 | Recruiting | Phase 2 | Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | June 10, 2024 | September 30, 2026 |
| NCT06073821 | Recruiting | Phase 3 | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | November 11, 2023 | December 2032 |
| NCT06084936 | Recruiting | Phase 3 | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | October 22, 2023 | December 31, 2026 |
| NCT06108232 | Recruiting | Phase 2 | Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma | March 15, 2024 | December 31, 2027 |
| NCT06295770 | Recruiting | Phase 2 | Obinutuzumab in Treatment of Fibrillary Glomerulonephritis | June 24, 2024 | May 2026 |
| NCT06175000 | Recruiting | Phase 2 | Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response | March 13, 2024 | September 15, 2029 |
| NCT06191744 | Recruiting | Phase 3 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | February 5, 2024 | May 18, 2037 |
| NCT06192888 | Recruiting | Phase 1 | A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | January 8, 2024 | January 8, 2028 |
| NCT06213311 | Recruiting | Phase 2 | A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | May 7, 2024 | January 1, 2027 |
| NCT03824483 | Recruiting | Phase 2 | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | February 22, 2019 | February 2025 |
| NCT03516617 | Recruiting | Phase 2 | Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | September 10, 2018 | March 15, 2026 |
| NCT03492125 | Recruiting | Phase 1/Phase 2 | A Study Of The Selective PKC-β Inhibitor MS- 553 | May 25, 2018 | June 15, 2024 |
| NCT03980171 | Recruiting | Phase 1/Phase 2 | Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma | August 19, 2019 | November 2026 |
| NCT04077723 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | August 13, 2019 | March 31, 2025 |
| NCT04169737 | Recruiting | Phase 2 | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | July 29, 2020 | July 9, 2026 |
| NCT04269902 | Recruiting | Phase 3 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | March 2, 2021 | October 1, 2028 |
| NCT04277637 | Recruiting | Phase 1 | Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | March 24, 2020 | August 30, 2027 |
| NCT03269669 | Recruiting | Phase 2 | Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | January 23, 2018 | December 31, 2025 |
| NCT04408638 | Recruiting | Phase 3 | A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | February 23, 2021 | April 15, 2025 |
| NCT03223610 | Recruiting | Phase 1/Phase 2 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | February 9, 2018 | December 1, 2026 |
| NCT04450173 | Recruiting | Phase 2 | Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | February 24, 2021 | April 2025 |
| NCT03198026 | Recruiting | Phase 2 | Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas | February 20, 2018 | February 20, 2031 |
| NCT04505254 | Recruiting | Phase 2 | Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | August 25, 2020 | June 1, 2024 |
| NCT04560322 | Recruiting | Phase 2 | Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL | October 19, 2020 | March 1, 2025 |
| NCT03075696 | Recruiting | Phase 1/Phase 2 | A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | February 21, 2017 | August 28, 2025 |
| NCT02846623 | Recruiting | Phase 2 | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | January 31, 2017 | February 28, 2025 |
| NCT04739813 | Recruiting | Phase 1 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | July 9, 2021 | July 15, 2029 |
| NCT04843904 | Recruiting | Phase 1 | Safe Accelerated Venetoclax Escalation in CLL | April 14, 2021 | June 2, 2030 |
| NCT04855695 | Recruiting | Phase 1/Phase 2 | Avo In R/R And Previously Untreated MCL | July 2, 2021 | June 1, 2026 |
| NCT04883437 | Recruiting | Phase 2 | Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | September 3, 2021 | January 15, 2024 |
| NCT04889716 | Recruiting | Phase 2 | CAR-T Followed by Bispecific Antibodies | November 5, 2021 | December 31, 2025 |
| NCT04895436 | Recruiting | Phase 2 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | March 28, 2022 | January 28, 2029 |
| NCT06333262 | Recruiting | Phase 2 | Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | April 22, 2024 | February 1, 2029 |
| NCT04934930 | Recruiting | Phase 2 | Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status | January 29, 2020 | August 1, 2025 |
| NCT04963296 | Recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus | October 26, 2021 | November 30, 2027 |
| NCT04970901 | Recruiting | Phase 1 | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | June 17, 2022 | February 10, 2026 |
| NCT02393157 | Recruiting | Phase 2 | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | August 21, 2015 | December 2024 |
| NCT05039619 | Recruiting | Phase 2 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants | May 12, 2022 | March 13, 2029 |
| NCT05100862 | Recruiting | Phase 3 | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | March 10, 2022 | June 2030 |
| NCT05169515 | Recruiting | Phase 1 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | October 26, 2022 | July 15, 2028 |
| NCT05169658 | Recruiting | Phase 2 | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | March 23, 2022 | December 1, 2025 |
| NCT05197192 | Recruiting | Phase 3 | A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | April 19, 2022 | February 2027 |
| NCT05219513 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | February 18, 2022 | April 30, 2025 |
| NCT05322733 | Recruiting | Phase 2 | Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL | April 15, 2022 | November 5, 2025 |
| NCT05326308 | Recruiting | Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma | April 26, 2022 | April 2027 | |
| NCT05336812 | Recruiting | Phase 2 | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia | September 13, 2022 | December 31, 2024 |
| NCT03432741 | Suspended | Phase 1 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | March 27, 2018 | May 1, 2026 |
| NCT04023071 | Terminated | Phase 1 | FT516 in Subjects With Advanced Hematologic Malignancies | October 4, 2019 | October 23, 2023 |
| NCT03539484 | Terminated | Phase 1 | A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors | July 4, 2018 | July 22, 2019 |
| NCT03759184 | Terminated | Phase 1 | Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | July 11, 2019 | October 22, 2021 |
| NCT02670317 | Terminated | Phase 2 | Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. | September 2016 | February 2017 |
| NCT02624986 | Terminated | Phase 1/Phase 2 | A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants | December 23, 2015 | May 20, 2019 |
| NCT02612311 | Terminated | Phase 3 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia | November 19, 2015 | February 22, 2023 |
| NCT04722601 | Terminated | Phase 1/Phase 2 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma | September 1, 2021 | March 31, 2023 |
| NCT02391545 | Terminated | Phase 1/Phase 2 | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) | December 2014 | May 2017 |
| NCT04073147 | Terminated | Phase 1 | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma | May 12, 2020 | November 25, 2021 |
| NCT04245722 | Terminated | Phase 1 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | March 19, 2020 | September 27, 2023 |
| NCT01980875 | Terminated | Phase 3 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | April 21, 2015 | May 13, 2016 |
| NCT02420210 | Terminated | Phase 2 | Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma | November 2015 | August 2016 |
| NCT03311126 | Terminated | Phase 2 | Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma | October 19, 2017 | July 31, 2023 |
| NCT02336048 | Terminated | Phase 1 | A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities | June 26, 2015 | September 21, 2018 |
| NCT05376319 | Terminated | Phase 2 | PR3-AAV Resilient Remission or PRRR | June 30, 2023 | May 7, 2024 |
| NCT03229382 | Terminated | Phase 2 | Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse | May 14, 2018 | January 31, 2020 |
| NCT02225275 | Terminated | Phase 2 | Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | March 31, 2016 | May 19, 2021 |
| NCT01287741 | Terminated | Phase 3 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | July 26, 2011 | January 31, 2018 |
| NCT02292225 | Terminated | Phase 1 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) | February 2015 | November 2016 |
| NCT03153514 | Terminated | Phase 2 | Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation | November 13, 2017 | June 6, 2019 |
| NCT03145480 | Terminated | Phase 2 | Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients | June 19, 2017 | September 28, 2018 |
| NCT03890289 | Terminated | Phase 2 | Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma | October 18, 2019 | May 10, 2023 |
| NCT03135262 | Terminated | Phase 1/Phase 2 | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) | June 15, 2017 | April 30, 2020 |
| NCT04059081 | Unknown status | Phase 2 | A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment | July 9, 2019 | July 8, 2022 |
| NCT03086395 | Withdrawn | Phase 2 | Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD) | April 1, 2017 | January 1, 2021 |
| NCT02611908 | Withdrawn | Phase 1 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. | June 2016 | November 2020 |
| NCT02371590 | Withdrawn | Phase 2 | Lenalidomide and Obinutuzumab for Previously Untreated CLL | February 2018 | December 2022 |
| NCT03369964 | Withdrawn | Phase 1 | A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | March 14, 2018 | August 31, 2019 |
| NCT04796922 | Withdrawn | Phase 3 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | December 30, 2022 | August 25, 2032 |
| NCT05894447 | Withdrawn | Phase 1 | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers | November 2023 | June 2028 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Gazyva
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2013
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- Phase III
- Target (Drug list of Screening Committee of Anticancer Drugs)
- CD20
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- CLL